Page last updated: 2024-12-05

n-isopropylacrylamide

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-isopropylacrylamide (NIPAM) is a monomer that undergoes a reversible phase transition from a hydrophilic to a hydrophobic state upon heating. It is widely studied for its applications in various fields, including drug delivery, biomaterials, and responsive polymers. NIPAM is synthesized through the reaction of isopropylamine with acryloyl chloride. The resulting polymer, poly(N-isopropylacrylamide) (PNIPAM), exhibits a lower critical solution temperature (LCST) around 32°C in water. At temperatures below the LCST, PNIPAM is soluble in water due to the presence of hydrogen bonding between the polymer chains and water molecules. However, as the temperature rises above the LCST, the hydrophobic interactions between the isopropyl groups become dominant, leading to phase separation and the formation of a collapsed polymer network. This temperature-responsive behavior of PNIPAM makes it highly versatile for various applications. For example, PNIPAM-based hydrogels can be used for controlled drug release, where the drug is encapsulated within the hydrogel and released upon reaching the desired temperature. In biomaterials, PNIPAM is used to create stimuli-responsive surfaces that can alter their properties in response to temperature changes, allowing for the development of new biocompatible materials and devices. The importance of NIPAM lies in its ability to respond to environmental stimuli, such as temperature, making it a valuable tool for various technological applications. Its properties, such as its LCST and reversible phase transition, allow for the creation of smart materials with tunable properties, opening up possibilities for advancements in fields like drug delivery, biomedicine, and environmental science.'

N-isopropylacrylamide: can polymerize with glycidyl acrylate to form reactive water-soluble polymer that can react with the amino groups of enzymes-proteins or other ligands [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID16637
CHEMBL ID1527236
SCHEMBL ID13341547
SCHEMBL ID15072
MeSH IDM0184508

Synonyms (69)

Synonym
hsdb 5868
nsc 11448
ai3-19343
brn 1744926
einecs 218-638-5
isopropylamid kyseliny akrylove [czech]
n-(1-methylethyl)-2-propenamide
acrylamide, n-isopropyl-
nsc-11448
isopropyl acrylamide
2-propenamide, n-(1-methylethyl)-
nsc11448
2210-25-5
wln: 1y1&mv1u1
n-isopropylacrylamide
nipam
NCGC00090689-01
n-isopropyl acrylamide
n-isopropylacrylamide, 97%
25189-55-3
AKOS000280149
MLS001055455
smr001227200
n-propan-2-ylprop-2-enamide
qniltegfhqskff-uhfffaoysa-
inchi=1/c6h11no/c1-4-6(8)7-5(2)3/h4-5h,1h2,2-3h3,(h,7,8)
I0401
A18467
NCGC00090689-02
4-04-00-00517 (beilstein handbook reference)
b7gff17l9u ,
unii-b7gff17l9u
isopropylamid kyseliny akrylove
n-iso-propylacrylamide
dtxcid8013754
tox21_200738
dtxsid0033754 ,
cas-2210-25-5
NCGC00258292-01
FT-0689126
AM84785
n-isopropylpropenamide
isopropylacrylamide
isopropylacrylamide [inci]
n-isopropylacrylamide [hsdb]
SCHEMBL13341547
SCHEMBL15072
n-isopropyl-acrylamide
n-isopropylacrylamide, stabilized with mehq
CHEMBL1527236
J-523613
n-sopropylacrylamde
n-isopropylacrylamide, >=99%
mfcd00041913
n-isopropylacrylamide (stabilized with mehq)
n-isopropylacrylamide, (stabilized with mehq)
SY010883
CS-W011259
FT-0700646
Q21012199
AS-18956
EN300-67477
D70366
n-isopropylacryl amide
n-iso-propyl-d7-acrylamide
1219803-32-3
poly(n-isopropyl acrylamide)
n-(propan-2-yl)prop-2-enamide
propenamide, n-(1-methylethyl)-

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" Overall, the HG properties, together with its natural and eco-friendly composition, create a safe and efficient platform for the local treatment of non-resectable tumors or tumors requiring pre-surgical adjuvant therapy."( Smart and eco-friendly N-isopropylacrylamide and cellulose hydrogels as a safe dual-drug local cancer therapy approach.
Abasolo, I; Andrade, F; Durán-Lara, EF; Hide, D; Llaguno, M; Martell, M; Oliva, M; Rafael, D; Raurell, I; Roca-Melendres, MM; Schwartz, S; Vijayakumar, S, 2022
)
1.03

Bioavailability

ExcerptReferenceRelevance
"Paclitaxel (PTX), a hydrophobic anticancer drug, is facing several clinical limitations such as low bioavailability and drug resistance."( Thermoresponsive Delivery of Paclitaxel by β-Cyclodextrin-Based Poly(N-isopropylacrylamide) Star Polymer via Inclusion Complexation.
Li, J; Song, X; Wen, Y; Zhang, ZX; Zhao, F; Zhu, JL, 2016
)
0.67
" Therapeutic angiogenesis has been one approach to address the major clinical need for a more effective treatment to restoring blood flow in ischemic organs and tissues, but current progress in angiogenic drug delivery is inadequate at providing sufficient bioavailability without causing safety concerns."( A sulfonated reversible thermal gel for the spatiotemporal control of VEGF delivery to promote therapeutic angiogenesis.
Bardill, JR; Lee, DJ; Park, D; Rocker, AJ; Shandas, R, 2018
)
0.48
" Compared to conventional agents, they increase bioavailability and efficacy."( Metabolite Responsive Nanoparticle-Protein Complex.
Fruehauf, KR; Kim, TI; Nelson, EL; Patterson, JP; Shea, KJ; Wang, SW, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
" In the preparation of P(NIPAM-co-St) seeds, with increasing the initiator dosage, the mean diameters and the dispersal coefficients were almost at the same levels at first; however, when the initiator dosage increased further to a critical amount, the mean diameters decreased drastically and the monodispersity became worse significantly."( Preparation of submicrometer-sized monodispersed thermoresponsive core-shell hydrogel microspheres.
Chen, WM; Chu, LY; Wang, S; Xiao, XC; Xie, R, 2004
)
0.32
" These thermoresponsive polymers may have several potential pharmaceutical applications such as ingredient for oral solid dosage form."( Preparation of poly(N-isopropylacrylamide) copolymers and preliminary assessment of their acute and subacute toxicity in mice.
Amighi, K; Eeckman, F; Fontaine, D; Fontaine, J; Malonne, H; Moës, A; Otto, A; Vos, LD, 2005
)
0.65
" It was shown that the dose-response behaviour of the NIPAM/Bis gel dosimeter is comparable to that of normoxic polyacrylamide gel (PAGAT) in terms of high dose-sensitivity and low dependence on dose rate and irradiation temperature, within the ranges considered."( Polymer gel dosimeters with reduced toxicity: a preliminary investigation of the NMR and optical dose-response using different monomers.
De Jean, P; McAuley, KB; Schreiner, LJ; Senden, RJ, 2006
)
0.33
" The dosage of drug (rhodamine B) released in these cycles could be controlled to deliver approximately equal doses by altering the release time in the swollen state."( A mathematical model for pulsatile release: controlled release of rhodamine B from UV-crosslinked thermoresponsive thin films.
Aldabbagh, F; Carroll, WM; Gorelov, AV; Meere, MG; Rochev, Y; Vo T N, T; Yang, R, 2012
)
0.38
" The dose-response sensitivity of the NIPAM gels was evaluated using the differences in optical densities."( A novel thin NIPAM gel cassette dosimeter for photon-beam radiotherapy.
Cheng, KY; Hsieh, BT; Hsieh, LL, 2012
)
0.38
"It was shown that the dose-response of NIPAM gel made from non-electrophoresis grade BIS is coincident to that of electrophoresis grade BIS."( Dosimetric properties of N-isopropylacrylamide polymer gel using nonelectrophoresis grade BIS in preparation.
Farajollahi, AR; Hajalioghli, P; Khajeali, A; Khodadadi, R; Ziaei, JE,
)
0.43
" Long-term and high dosage use of antibacterial agents is the main reason."( Dual layered wound dressing with simultaneous temperature & antibacterial regulation properties.
Dong, L; Guo, G; Li, F; Liu, M; Miao, X; Min, D; Wang, X; Xing, J; Zhang, H, 2019
)
0.51
" A dose-response curve from 1 to 12 Gy was created."( Using an on-board cone-beam computed tomography scanner as an imaging modality for gel dosimetry: A feasibility study.
Hsieh, BT; Shih, TY; Wu, J, 2019
)
0.51
"Controlled release is at the forefront of modern bioscience as it aims to address challenges associated with the dosing of drugs within required levels for therapeutic effect."( Tuning drug dosing through matching optically active polymer composition and NIR stimulation parameters.
Del Rosal, B; Gietman, SW; Kapsa, RMI; Moulton, SE; Silva, SM; Stoddart, PR, 2020
)
0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (3)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
thyroid stimulating hormone receptorHomo sapiens (human)Potency15.84890.001318.074339.8107AID926; AID938
retinoid X nuclear receptor alphaHomo sapiens (human)Potency42.37350.000817.505159.3239AID1159527; AID1159531
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency37.57800.000627.21521,122.0200AID651741
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (567)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's24 (4.23)18.2507
2000's157 (27.69)29.6817
2010's326 (57.50)24.3611
2020's60 (10.58)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 52.17

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index52.17 (24.57)
Research Supply Index6.38 (2.92)
Research Growth Index5.19 (4.65)
Search Engine Demand Index82.86 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (52.17)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.17%)5.53%
Reviews6 (1.02%)6.00%
Case Studies1 (0.17%)4.05%
Observational0 (0.00%)0.25%
Other581 (98.64%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]